Mitchell G. Lawrence

This study uses single-cell RNA sequencing to show that focal neuroendocrine differentiation (Focal NED) in prostate cancer is transcriptionally distinct, characterized by androgen receptor expression and unique transcriptional sub-populations.

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.

This study identifies distinct morphomechanical features of prostate cancer-associated fibroblasts (CAFs) linked to patient outcomes and shows these features can be modulated by cancer treatments.

This study shows estrogen receptor alpha (ER) regulates gene expression by coordinating transcription with translational offsetting, maintaining protein levels despite changes in mRNA abundance.